A total number of 24, 9 and

99 HIV, HBV and HCV positive tests were obtained respectively. Of these, 4, 4 and 15 were new diagnoses respectively. The remainder were previously known. New diagnosis rates for HIV, HBV and HCV were 1.94, 1.94 and 7.2 per 1000 respectively. 95% (n=19) of known HIV patients were linked to care and to date 75% (n=3) of new patients have been linked to care. 80% (n=5) of known HBV patients have been linked to care and to date 100% (n=4) of new patients have been linked to care. Only 60.7% Erlotinib supplier (n=51) of those with previously known HCV are linked to care and to date 40% (n=6) of new patients have been linked to care. Conclusion A high feasibility and acceptability rate has been achieved at an early point in this study with target uptake rates of greater than 50% achieved. The above HIV prevalence rates have supported recent data and a high rate of new diagnoses for HBV and HCV has been found. High HCV prevalence rates amongst emergency department attendees are noted with a difference in linkage to care rates in this virus group. These results suggest a roll out to widespread ED testing in urban areas is warranted. Panel testing

may be more cost effective for this purpose. Disclosures: Catherine Fleming – Advisory Ponatinib chemical structure Committees or Review Panels: BMS Suzanne Norris – Advisory Committees or Review Panels: AbbVie Colm J. Bergin – Advisory Committees or Review Panels: Abbvie, BMS, Janssen; Consulting: Gilead; Grant/Research Support: Abbvie, MSD, Gilead The following people have nothing to disclose: Sarah O’Connell, Darren Lillis, Siobhan O’Dea, Helen Tuite,

Helen Barry, Linda Dalby, Darragh Shields, Brendan Crowley, Patrick learn more K. Plunkett Introduction: Despite therapeutic advances and concerted efforts to identify hepatitis C virus (HCV) infected individuals and enroll them into therapy, treatment rates for patients, especially veterans and other vulnerable populations, remain modest. In light of new therapies for HCV and given the challenges of maximizing treatment for at-risk populations, we explored predictors of initiating treatment in a veteran population. We hypothesized that patient-related factors, such as living situation and employment, as well as patient knowledge of HCV would be significantly associated with initiating antiviral therapy. Methods: We recruited veterans from the VA Pittsburgh Healthcare System between December 2006-June 2010, after they were referred for HCV treatment. They were asked to complete the following validated measures: the Medical Interview Satisfaction Scale (MISS), Patient Education About Hepatitis C (PEAHC), the Center for Epidemiologic Studies-Depression Survey (CES-D), the Alcohol Use Disorders Identification Test (AUDIT), and the Drug Abuse Screening Test (DAST). Patient initiation of treatment was determined based on a chart review which tracked individuals 18 months from their referral date.